ID

30846

Description

Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00560352

Lien

https://clinicaltrials.gov/show/NCT00560352

Mots-clés

Versions (2)
  1. 26/06/2018 26/06/2018 -
  2. 26/06/2018 26/06/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

26 juin 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Multiple Myeloma NCT00560352

Anglais

Eligibility Multiple Myeloma NCT00560352

1 Formulaires  
Criteria
Description

Criteria

confirmed diagnosis of multiple myeloma with measurable disease
Description

Multiple Myeloma | Measurable Disease

Type de données

boolean

Alias
UMLS CUI [1]
C0026764
UMLS CUI [2]
C1513041
evidence of relapsed or refractory disease and at least 2 prior therapies for multiple myeloma
Description

Recurrent disease | Refractory Disease | Prior Therapy Quantity Multiple Myeloma

Type de données

boolean

Alias
UMLS CUI [1]
C0277556
UMLS CUI [2]
C1514815
UMLS CUI [3,1]
C1514463
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0026764
eastern cooperative oncology group performance status of 0 - 2
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
last treatment for multiple myeloma not within 21 days prior to study treatment initiation
Description

Timepoint Therapeutic procedure Last Multiple Myeloma

Type de données

boolean

Alias
UMLS CUI [1,1]
C2348792
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C1517741
UMLS CUI [1,4]
C0026764
bone marrow transplant not within 3 months prior to study treatment initiation
Description

Timepoint Bone Marrow Transplantation

Type de données

boolean

Alias
UMLS CUI [1,1]
C2348792
UMLS CUI [1,2]
C0005961
required baseline hematology and chemistry parameters.
Description

Hematology Parameters Required | Chemistry Parameters Required

Type de données

boolean

Alias
UMLS CUI [1,1]
C0200627
UMLS CUI [1,2]
C0449381
UMLS CUI [1,3]
C1514873
UMLS CUI [2,1]
C0201682
UMLS CUI [2,2]
C0449381
UMLS CUI [2,3]
C1514873
key exclusion criteria:
Description

Exclusion Criteria Main

Type de données

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
clinically significant cardiac disease (new york heart association class iii or iv)
Description

Heart Disease New York Heart Association Classification

Type de données

boolean

Alias
UMLS CUI [1,1]
C0018799
UMLS CUI [1,2]
C1275491
abnormal qt interval corrected for heart rate using fridericia's formula prolonged (>450 msec) after electrolytes have been corrected on baseline electrocardiogram
Description

Electrocardiogram QT corrected interval prolonged Fridericia formula

Type de données

boolean

Alias
UMLS CUI [1,1]
C0855333
UMLS CUI [1,2]
C4037934
malabsorption syndrome or uncontrolled gastrointestinal toxicities
Description

Malabsorption Syndrome | Gastrointestinal toxicity Uncontrolled

Type de données

boolean

Alias
UMLS CUI [1]
C0024523
UMLS CUI [2,1]
C1142499
UMLS CUI [2,2]
C0205318
dementia, chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation
Description

Dementia Study Subject Participation Status At risk | Medical condition chronic Study Subject Participation Status At risk | Chronic mental disorder Study Subject Participation Status At risk | Laboratory test result abnormal Study Subject Participation Status At risk

Type de données

boolean

Alias
UMLS CUI [1,1]
C0497327
UMLS CUI [1,2]
C2348568
UMLS CUI [1,3]
C1444641
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0205191
UMLS CUI [2,3]
C2348568
UMLS CUI [2,4]
C1444641
UMLS CUI [3,1]
C0870281
UMLS CUI [3,2]
C2348568
UMLS CUI [3,3]
C1444641
UMLS CUI [4,1]
C0438215
UMLS CUI [4,2]
C2348568
UMLS CUI [4,3]
C1444641
clinically significant pleural effusion in the previous 12 months or current ascites
Description

Pleural effusion | Ascites

Type de données

boolean

Alias
UMLS CUI [1]
C0032227
UMLS CUI [2]
C0003962
clinically significant coagulation or platelet function disorder
Description

Blood Coagulation Disorders | Impaired platelet function

Type de données

boolean

Alias
UMLS CUI [1]
C0005779
UMLS CUI [2]
C3550794
intolerance to dasatinib and/or bortezomib
Description

Intolerance to Dasatinib | Intolerance to Bortezomib

Type de données

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C1455147
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C1176309
acute diffuse infiltrative pulmonary disease
Description

Acute diffuse infiltrative lung disease

Type de données

boolean

Alias
UMLS CUI [1]
C1735346
prior or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, adequately treated stage i or ii cancer currently in complete remission, cervical carcinoma in situ, or any other cancer from which the participant has been disease-free for 3 years.
Description

Malignant Neoplasms | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Malignant Neoplasm TNM clinical staging Treated | Exception Malignant Neoplasm In complete remission | Exception Carcinoma in situ of uterine cervix | Exception Disease Free of

Type de données

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0007117
UMLS CUI [2,3]
C1522326
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0553723
UMLS CUI [3,3]
C1522326
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0006826
UMLS CUI [4,3]
C3258246
UMLS CUI [4,4]
C1522326
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0006826
UMLS CUI [5,3]
C0677874
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0851140
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0012634
UMLS CUI [7,3]
C0332296
Retour au début de la page

Similar models

Eligibility Multiple Myeloma NCT00560352

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Multiple Myeloma | Measurable Disease
Item
confirmed diagnosis of multiple myeloma with measurable disease
boolean
C0026764 (UMLS CUI [1])
C1513041 (UMLS CUI [2])
Recurrent disease | Refractory Disease | Prior Therapy Quantity Multiple Myeloma
Item
evidence of relapsed or refractory disease and at least 2 prior therapies for multiple myeloma
boolean
C0277556 (UMLS CUI [1])
C1514815 (UMLS CUI [2])
C1514463 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0026764 (UMLS CUI [3,3])
ECOG performance status
Item
eastern cooperative oncology group performance status of 0 - 2
boolean
C1520224 (UMLS CUI [1])
Timepoint Therapeutic procedure Last Multiple Myeloma
Item
last treatment for multiple myeloma not within 21 days prior to study treatment initiation
boolean
C2348792 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C1517741 (UMLS CUI [1,3])
C0026764 (UMLS CUI [1,4])
Timepoint Bone Marrow Transplantation
Item
bone marrow transplant not within 3 months prior to study treatment initiation
boolean
C2348792 (UMLS CUI [1,1])
C0005961 (UMLS CUI [1,2])
Hematology Parameters Required | Chemistry Parameters Required
Item
required baseline hematology and chemistry parameters.
boolean
C0200627 (UMLS CUI [1,1])
C0449381 (UMLS CUI [1,2])
C1514873 (UMLS CUI [1,3])
C0201682 (UMLS CUI [2,1])
C0449381 (UMLS CUI [2,2])
C1514873 (UMLS CUI [2,3])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Heart Disease New York Heart Association Classification
Item
clinically significant cardiac disease (new york heart association class iii or iv)
boolean
C0018799 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
Electrocardiogram QT corrected interval prolonged Fridericia formula
Item
abnormal qt interval corrected for heart rate using fridericia's formula prolonged (>450 msec) after electrolytes have been corrected on baseline electrocardiogram
boolean
C0855333 (UMLS CUI [1,1])
C4037934 (UMLS CUI [1,2])
Malabsorption Syndrome | Gastrointestinal toxicity Uncontrolled
Item
malabsorption syndrome or uncontrolled gastrointestinal toxicities
boolean
C0024523 (UMLS CUI [1])
C1142499 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
Dementia Study Subject Participation Status At risk | Medical condition chronic Study Subject Participation Status At risk | Chronic mental disorder Study Subject Participation Status At risk | Laboratory test result abnormal Study Subject Participation Status At risk
Item
dementia, chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation
boolean
C0497327 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
C1444641 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
C1444641 (UMLS CUI [2,4])
C0870281 (UMLS CUI [3,1])
C2348568 (UMLS CUI [3,2])
C1444641 (UMLS CUI [3,3])
C0438215 (UMLS CUI [4,1])
C2348568 (UMLS CUI [4,2])
C1444641 (UMLS CUI [4,3])
Pleural effusion | Ascites
Item
clinically significant pleural effusion in the previous 12 months or current ascites
boolean
C0032227 (UMLS CUI [1])
C0003962 (UMLS CUI [2])
Blood Coagulation Disorders | Impaired platelet function
Item
clinically significant coagulation or platelet function disorder
boolean
C0005779 (UMLS CUI [1])
C3550794 (UMLS CUI [2])
Intolerance to Dasatinib | Intolerance to Bortezomib
Item
intolerance to dasatinib and/or bortezomib
boolean
C1744706 (UMLS CUI [1,1])
C1455147 (UMLS CUI [1,2])
C1744706 (UMLS CUI [2,1])
C1176309 (UMLS CUI [2,2])
Acute diffuse infiltrative lung disease
Item
acute diffuse infiltrative pulmonary disease
boolean
C1735346 (UMLS CUI [1])
Malignant Neoplasms | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated | Exception Malignant Neoplasm TNM clinical staging Treated | Exception Malignant Neoplasm In complete remission | Exception Carcinoma in situ of uterine cervix | Exception Disease Free of
Item
prior or concurrent malignancy, except for adequately treated basal cell or squamous cell skin cancer, adequately treated stage i or ii cancer currently in complete remission, cervical carcinoma in situ, or any other cancer from which the participant has been disease-free for 3 years.
boolean
C0006826 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1522326 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0553723 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0006826 (UMLS CUI [4,2])
C3258246 (UMLS CUI [4,3])
C1522326 (UMLS CUI [4,4])
C1705847 (UMLS CUI [5,1])
C0006826 (UMLS CUI [5,2])
C0677874 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0851140 (UMLS CUI [6,2])
C1705847 (UMLS CUI [7,1])
C0012634 (UMLS CUI [7,2])
C0332296 (UMLS CUI [7,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial